CLEARSIDE BIOMEDICAL

Eyecelerator Company Showcase October 17, 2024

Victor Chong MD MBA CMO and EVP Clearside Biomedical, Inc.

Forward-Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "may," "will," "could," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "project," "potential," "continue," "target" or the negative of these terms and other similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Clearside Biomedical, Inc.'s views as of the date of this presentation about future events and are subject to risks, uncertainties, assumptions, and changes in circumstances that may cause Clearside's actual results, performance, or achievements to differ significantly from those expressed or implied in any forward-looking statement. These forward looking statements include statements regarding the clinical development of CLS-AX, the timing of correspondence with regulatory authorities, and the trial design features of a potential Phase 3 trial. Although Clearside believes that the expectations reflected in the forward-looking statements are reasonable, new risks and uncertainties may emerge from time to time, and Clearside cannot guarantee future events, results, performance, or achievements. Some of the key factors that could cause actual results to differ from Clearside's expectations include its plans to develop and potentially commercialize its product candidates; adverse differences between preliminary or interim data and final data; Clearside's planned clinical trials and preclinical studies for its product candidates; the timing of and Clearside's ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Clearside's product candidates; the clinical utility and market acceptance of Clearside's product candidates; Clearside's commercialization, marketing and manufacturing capabilities and strategy; Clearside's intellectual property position; Clearside's ability to expand its pipeline; developments and projections relating to Clearside's competitors and its industry; the impact of government laws and regulations; the timing and anticipated results of Clearside's preclinical studies and clinical trials and the risk that the results of Clearside's preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; findings from investigational review boards at clinical trial sites and publication review bodies; Clearside's estimates regarding future revenue, expenses, capital requirements and need for additional financing; and Clearside's ability to identify additional product candidates with significant commercial potential that are consistent with its commercial objectives. For further information regarding these risks, uncertainties and other factors you should read the "Risk Factors" section of Clearside's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC) on March 12, 2024, Clearside's Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024, and Clearside's subsequent filings with the SEC. Clearside expressly disclaims any obligation to update or revise the information herein, including the forward-looking statements, except as required by law. In addition, projections, assumptions and estimates of Clearside's future performance and the future performance of the markets in which Clearside operates are necessarily subject to a high degree of uncertainty and risk.

Delivering on the Potential of the Suprachoroidal Space

Validated Suprachoroidal Space (SCS) Delivery with Approved Product, Multiple Collaborations, and Comprehensive IP Portfolio

Proven Leader in Suprachoroidal Delivery with Thousands of Injections Performed in the Clinic



Differentiated SCS Clinical Program Targeting Multi-Billion Dollar Wet AMD Market



Straightforward Suprachoroidal Injection Technique




REVIEW

SUPRACHOROIDAL SPACE INJECTION TECHNIQUE


Expert Panel Guidance

Wykoff, Charles C. MD, PhD^{*}; Avery, Robert L. MD[†]; Barakat, Mark R. MD^{1,5}; Boyer, David S. MD[§]; Brown, David M. MD[°]; Brucker, Alexander J. MD^{**}; Cunningham, Emmett T. Jr MD, PhD, MPH^{11,11,155, S[§]}; Heier, Jeffrey S. MD^{***}; Holekamp, Nancy M. MD^{111,111}; Kaiser, Peter K. MD⁵⁵⁵; Khanani, Arshad M. MD, MAS^{§§}. Kim, Judy E. MD^{111,111}; Demirci, Hakan MD¹¹¹¹; Regillo, Carl D. MD⁵⁵⁵⁵; Yiu, Glenn C. MD, PhD^{§§§}1[§]; Ciulla, Thomas A. MD, MBA^{*****}



Perpendicular

Hold the microinjector **perpendicular** to the ocular surface



Dimple

Ensure firm contact with sclera by maintaining a **dimple** throughout injection

RETINA SPECIALIST

A beginner's guide to suprachoroidal injections

They require a different skill set than intravitreal injections. Here's a description of the technique.

By Carol Villafuerte-Trisolini, MD, and Glenn Yiu, MD, PhD

DECEMBER 23, 2023




Slow

Inject **slowly** over 5 – 10 seconds



SCS Microinjector[®]: Drug/Device Combination with Proven Versatility



SUPRACHOROIDAL SPACE INJECTION

Novel SCS Microinjector[®] shows a demonstrated ability for precise delivery into the suprachoroidal space





Multiple clinical trials with 4 potential therapies in 5 indications: Wet AMD, UME, DME, DR, Choroidal Melanoma



Safety profile of SCS Microinjector comparable to intravitreal injections¹



Well-accepted by retinal physicians with thousands of injections performed to date



30-gauge needle equivalent to most commonly used intravitreal injections Smaller than tyrosine kinase inhibitor (TKI) competitors in development



Abbreviations: UME = uveitic macular edema; DME = diabetic macular edema; DR = diabetic retinopathy; Sources: Clearside data on file | 1Kurup, et. al, Macula Society 2021 Safety of the Suprachoroidal Injection Procedure Utilizing SCS Microinjector® across Three Retinal Disorders.

Diverse Programs Using Clearside's Suprachoroidal Injection Platform

Clearside Developed Programs										
THERAPEUTIC	ТҮРЕ	INDICATION	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3	APPROVAL	PARTNER		
CLS-AX (axitinib):	Tyrosine Kinase Inhibitor	Wet AMD	Phase 2b - Completed							
XIPERE [®]	Corticosteroid (Triamcinolone Acetonide)	Uveitic Macular Edema ¹ (U.S. & Canada)						B+L BAUSCH+LOMB		
XIPERE [®] / ARCATUS™	Corticosteroid (Triamcinolone Acetonide)	Uveitic Macular Edema ² — Diabetic Macular Edema ² (Asia Pacific ex-Japan)				UME		O arctic VISION		
XIPERE [®] / ARCATUS™	Corticosteroid (Triamcinolone Acetonide)			DME				O arctic VISION		

SCS Microinjector[®] Partner Clinical Development Programs

THERAPEUTIC	ТҮРЕ	INDICATION	IND-ENABLING	PHASE 1	PHASE 2	PHASE 3	APPROVAL	PARTNER
Bel-Sar	Viral-like Drug Conjugate	Choroidal Melanoma	CoMpass					aura
ABBV-RGX-314	AAV Gene Therapy	Diabetic Retinopathy Diabetic Macular Edema		ALT	ITUDE			
ABBV-RGX-314	AAV Gene Therapy	Wet AMD		AA	VIATE			
Avoralstat	Plasma Kallikrein Inhibitor	Diabetic Macular Edema						biocryst




¹XIPER[®] (triamcinolone acetonide injectable suspension), for suprachoroidal use has received U.S. FDA Approval and is being commercialized by Bausch + Lomb. ²In China, Arctic Vision is responsible for clinical development of ARCATUS™ (triamcinolone acetonide injectable suspension), formerly referred to as ARVN001, and known as XIPERE[®] in the U.S.



Phase 2b Topline Data Results


Preliminary Topline Results Subject to Change 7

ODYSSEY Phase 2b Clinical Trial





CLS-AX Demonstrated Positive Efficacy Data in Wet AMD






Abbreviations: CST=Central Subfield Thickness Injection frequency reduction calculated by the average number of treatments 24 Weeks prior to Screening Visit as compared to Average number of treatments up to 24 Weeks after Baseline Visit.

Preliminary Topline Results Subject to Change

9

Two-Thirds of Participants Dosed with CLS-AX Reached Six Months Without Additional Treatment



Intervention-Free Rates By Week Up to Each Visit



Calculation accounts for missed treatments; time of initial administration of study drug shown as month 0 on figure. Intervention-free rate calculation: if participant received intervention at a study visit, those were reflected in the count at the following study visit.

Preliminary Topline Results Subject to Change 10

No Ocular SAEs and No Treatment-Related SAEs

- No drug or procedure-related ocular SAEs
- No reported drug or procedure-related systemic SAEs
- No endophthalmitis
- No retinal vasculitis
- Four cases of intraocular inflammation all deemed clinically mild by the Safety Review Committee
 - Two cases had minimal clinical signs that resolved
 - Two cases were potentially related to drug administration
 - In all four cases, the inflammation was no longer detected at or before Week 36



Pipeline Expansion Opportunity in Geographic Atrophy

Focusing on Choroidal Health and Capillary Homeostasis

Differentiated and Promising Approach

Neuroprotection

- Promising preclinical evidence
- Limited clinical success

Lipid pathway


- Complex lipid metabolism pathways
- Clinical effectiveness likely to require removal of lipid from Bruch's

Extracellular matrix modulation (HTRA1, TIMP3 & MMPs)

- Molecular mechanism is not controversial
- Anti-HTRA1 failed in clinical trial

Complement inhibition

- Clinically validated
- Approved therapies have limited efficacy



Visual cycle modulation

- Lacks robust clinical efficacy
- Multiple failed trials

Reduce choriocapillaris degeneration & improve choroidal perfusion

- Choriocapillaris degeneration precedes RPE and PR loss
- Implicated in the pathophysiology of AMD
- Warrants further clinical investigation


Control proinflammatory microenvironment

- Well-studied inflammatory pathways (macrophages, microglia, mast cells)
- Controls multiple disease-triggering insults




Geographic Atrophy is a Choroidal Disease


Choroidal Hypoxia Theory and Choriocapillaris are Damaged First



Choriocapillaris endothelial cells damage with ghost vessels before any significant RPE changes



- Choriocapillaris (CC) vascular density is significantly lower in GA donor
- No meaningful differences in vascular lumen area / stroma area




VEGF level increased with low vascular density support the choroidal hypoxia theory



1

Small Molecule Can Access the Diseased Area of the RPE and Choroid



Larger molecules cannot get through Bruch's membrane So, if given intravitreally, it can only treat the RPE side

Aging intensifies disease actions and even peptides might not be able to get through



Potential Target Product Profile (TPP) Aligns with SCS Suspension or SCS Gene Therapy

Able to reach the choroid first

• Fluid spreads circumferentially and posteriorly when injected within the suprachoroidal space, bathing the choroid, RPE, retina and adjacent areas with drug

Small molecules may have better efficacy than current therapies Potential to treat complement activation in both RPE and choroid

Suprachoroidal gene therapy – potentially better efficacy and might be safer

- Intravitreal gene therapy may not achieve efficacy
- Subretinal gene therapy has additional risks


Less invasive, in-office procedure with potential of longer duration (3 to 6 months)

- Systemic therapy may be effective, but potential infection risks in this elderly population
- Local ocular therapy may have fewer adverse events

Targeted delivery compartmentalized to the posterior segmentPotentially fewer ocular adverse events



Innovative and Experienced Leader in Suprachoroidal Drug Delivery



Upcoming Potential Catalysts

CLS-AX (axitinib injectable suspension)

- October 9, 2024: ODYSSEY Phase 2b Top Line Results
- H2 2024: Phase 3 Planning

Medical/Scientific meeting presentations

- ✓ Q1 2024: Macula Society; Next Generation Ophthalmic Drug Delivery Summit
- ✓ Q2 2024: Retina World Congress; Clinical Trials at the Summit
- Q4 2024: AAO; Asia-Pacific Vitreo-Retina Society; Ophthalmology Innovation Summit

Publications

- ✓ Q2 2024: Expert panel practice guidelines on SCS[®] delivery in *Retina*
- ✓ H2 2024: OASIS Data in Ophthalmology Science

